MISSISSAUGA, ON, July 2, 2024 /CNW/ - Kye Pharmaceuticals, Inc. ('Kye') announced today that QUILLIVANT® ER Chewable Tablets (methylphenidate hydrochloride extended-release chewable tablets) are now available in Canada. QUILLIVANT® ER Chewable Tablets are the first-and-only extended-release chewable methylphenidate tablets approved by Health Canada.

密西沙加，安大略省，2024年7月2日/CNW/-Kye Pharmaceuticals，Inc.（“Kye”）今天宣布，QUILLIVANT®ER咀嚼片（盐酸哌甲酯缓释咀嚼片）现已在加拿大上市。QUILLIVANT®ER咀嚼片是加拿大卫生部批准的第一种也是唯一一种缓释咀嚼哌醋甲酯片剂。

QUILLIVANT® ER Chewable Tablets are indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children six to 12 years of age.4.

QUILLIVANT®ER咀嚼片适用于治疗6至12岁儿童的注意力缺陷多动障碍（ADHD）。

QUILLIVANT® ER Chewable Tablets are indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD).

QUILLIVANT®ER咀嚼片适用于治疗注意力缺陷多动障碍（ADHD）。

'The launch of QUILLIVANT® ER Chewable Tablets in Canada marks a significant milestone in expanding the availability of novel, high-quality therapeutic options for physicians and patients living with ADHD,' said John McKendry, President and CEO, Kye Pharmaceuticals. 'The approval and launch of QUILLIVANT® ER Chewable Tablets is just the beginning of our commitment to serve families across Canada impacted by ADHD.'.

Kye Pharmaceuticals总裁兼首席执行官约翰·麦肯德里（JohnMcKendry）说：“QUILLIVANT®ER咀嚼片在加拿大的推出，标志着为多动症医生和患者扩大新型高质量治疗选择的重要里程碑。”QUILLIVANT®ER咀嚼片的批准和推出仅仅是我们致力于为加拿大受ADHD影响的家庭提供服务的开始。”。

Kye Pharmaceuticals supports Health Canada's Pediatric Drug Action Plan, which is designed to help ensure that children and youth in Canada have access not only to the medicines they need, but also to age-appropriate formulations.5 In addition to the currently available chewable tablets, Kye will launch an oral suspension formulation of QUILLIVANT® ER later this summer..

Kye Pharmaceuticals支持加拿大卫生部的儿科药物行动计划，该计划旨在帮助确保加拿大的儿童和青少年不仅可以获得所需的药物，还可以获得适合年龄的配方。5除了目前可用的咀嚼片剂外，Kye还将于今年夏天晚些时候推出QUILLIVANT®ER口服混悬剂配方。。

'The introduction of a chewable tablet formulation of methylphenidate with an innovative extended-release delivery system represents a major advancement for young Canadian patients and their caregivers managing ADHD,' said Sohail Khattak, MD, FRCP(C), paediatrician, pharmacologist and toxicologist at the Kids Clinic in Ajax, Ontario.

安大略省阿贾克斯儿童诊所的儿科医生、药理学家和毒理学家、医学博士、FRCP（C）Sohail Khattak说：“哌醋甲酯咀嚼片配方的推出，以及创新的缓释递送系统，代表了加拿大年轻患者及其管理ADHD的护理人员的重大进步。”。

'This novel approach ensures lasting effects and a convenient dosing regimen that enhances treatment adherence.'.

“这种新方法确保了持久的效果和方便的给药方案，增强了治疗依从性。”。

'As a child and adolescent psychiatrist, I am deeply aware of the challenges faced by children with ADHD and their families,' said Doron Almagor, MD, FRCPC, child and adolescent psychiatrist and Director, Possibilities Clinic. 'Methylphenidate has a proven track record in treating this condition. The introduction of QUILLIVANT® ER Chewable Tablets provides a new option for our therapeutic toolkit that could potentially improve convenience and adherence for patients.'.

“作为一名儿童和青少年精神病医生，我深深意识到多动症儿童及其家庭所面临的挑战，”儿童和青少年精神病医生兼可能性诊所主任、FRCPC医学博士多伦·阿尔马戈（DoronAlmagor）说哌醋甲酯在治疗这种疾病方面有着良好的记录。QUILLIVANT®ER咀嚼片的推出为我们的治疗工具包提供了一种新的选择，可能会提高患者的便利性和依从性。”。

Effective June 27, QUILLIVANT® ER Chewable Tablets are available to pharmacies across Canada.

自6月27日起，QUILLIVANT®ER咀嚼片可供加拿大各地的药店使用。

About ADHD

关于多动症

ADHD is a common childhood neurodevelopmental disorder leading to impairments in learning and behaviour. Patients with ADHD experience difficulties regulating their attention or focus. According to the Centre for ADHD Awareness, Canada (CADDAC), 80% of children diagnosed with ADHD continue to qualify for a diagnosis in adolescence, and at least 65% continue to be impaired by symptoms in adulthood.1 Although there are many treatment options for ADHD, QUILLIVANT® ER Chewable Tablets are the only once-daily, extended-release chewable methylphenidate option for the treatment of this condition available in Canada..

多动症是一种常见的儿童神经发育障碍，导致学习和行为障碍。多动症患者难以调节注意力或注意力。根据加拿大多动症意识中心（CADDAC）的数据，80%被诊断患有多动症的儿童在青春期仍有资格获得诊断，至少65%的儿童在成年后仍会受到症状的损害。1虽然多动症有许多治疗选择，但QUILLIVANT®ER咀嚼片是加拿大唯一一种每日一次的缓释咀嚼哌醋甲酯治疗方法。。

About QUILLIVANT® ER Chewable Tablets

关于QUILLIVANT®ER咀嚼片

QUILLIVANT® ER Chewable Tablet is approved in Canada for the treatment of ADHD in children six to 12 years of age. QUILLIVANT® is available as a once-daily chewable tablet. This easy to take, pediatric option provides the duration of effect needed to control ADHD symptoms throughout the day. QUILLIVANT® ER Chewable Tablets have demonstrated rapid onset of action and provide consistent, continuous delivery throughout the day, 8-12 hours post-dose6.

QUILLIVANT®ER咀嚼片在加拿大被批准用于治疗6至12岁儿童的ADHD。QUILLIVANT®可作为每日一次的咀嚼片提供。这种易于服用的儿科选择提供了全天控制ADHD症状所需的持续时间。QUILLIVANT®ER可咀嚼片剂已显示出快速起效，并在给药后8-12小时提供全天一致的连续递送6。

QUILLIVANT® ER Chewable Tablets are cherry-flavoured with scored options designed for pediatric patients, providing additional flexibility in dose administration. This unique formulation was designed by Tris Pharma with proprietary ionic exchange LiquiXR® technology which enables the sustained and extended release of methylphenidate in a chewable tablet throughout the day..

QUILLIVANT®ER咀嚼片是樱桃味的，带有专为儿科患者设计的评分选项，为剂量管理提供了额外的灵活性。这种独特的配方由Tris Pharma设计，采用专有的离子交换LiquiXR®技术，可以在一整天的咀嚼片剂中持续和延长哌醋甲酯的释放。。

About Tris Pharma

关于Tris Pharma

Tris Pharma is a privately held, innovation-driven biopharmaceutical company that is applying its drug development capabilities and proprietary technologies to transform the treatment of ADHD, pain, addiction and disorders of the central nervous system. Tris is an established commercial organization with a robust portfolio of best-in-class ADHD products and a promising pipeline of differentiated, near-term drug candidates.

Tris Pharma是一家私营、创新驱动的生物制药公司，正在应用其药物开发能力和专有技术来改变多动症、疼痛、成瘾和中枢神经系统疾病的治疗方法。Tris是一家成熟的商业组织，拥有一流的ADHD产品的强大组合，以及有前途的差异化近期候选药物渠道。

More information is available at www.trispharma.com and on LinkedIn @TrisPharma..

更多信息请访问www.trispharma.com和LinkedIn@trispharma。。

About Kye Pharmaceuticals

关于Kye Pharmaceuticals

Kye is a growth-stage Canadian specialty pharmaceutical company committed to bringing value to Canadians by identifying, licensing, and commercializing novel prescription medicines that may not otherwise be available to patients across Canada. Fueled by courage and agility, our corporate philosophy is rooted in the pursuit of innovation and driven by our entrepreneurial spirit.  With a growing pipeline of novel medicines, Kye's portfolio spans a range of therapeutic areas including cardiology, psychiatry, pediatrics, rare diseases, hematology, and neurology.

Kye是一家处于成长阶段的加拿大专业制药公司，致力于通过识别、许可和商业化加拿大各地患者可能无法获得的新型处方药，为加拿大人带来价值。在勇气和灵活性的推动下，我们的企业理念植根于创新的追求和创业精神的驱动。随着新药渠道的不断扩大，Kye的投资组合涵盖了一系列治疗领域，包括心脏病学、精神病学、儿科、罕见病、血液学和神经病学。

Kye Pharmaceuticals is a private company headquartered in Toronto focused on bringing medications to the Canadian market which fulfill clinically significant unmet needs. Kye is committed to licensing and launching medicines that matter by delivering better outcomes to our partners, Canadian healthcare professionals, and most importantly, patients across Canada.

Kye Pharmaceuticals是一家总部位于多伦多的私人公司，专注于将药物带入加拿大市场，以满足临床上重要的未满足需求。。